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ABSTRACT 
CC-1065, the duocarmycins and yatakemycin are members of a family of ultrapotent 
antitumour antibiotics that have been the subject of extensive investigations due to their mode 
of action and potential in the design of new anticancer therapeutics. The natural products and 
their analogues exert their effects through a sequence selective alkylation of duplex DNA in 
the minor groove at the N3 of adenine. An understanding of their structure and its effect on 
biological activity has been derived through chemical synthesis and has also generated new 
potential lead compounds. These studies form the first section of the review. The desire to 
progress these compounds to clinic has also led to studies of bioconjugation and prodrug 
formation and this is discussed in the second section of the review. The combination of 
synthesis with key biological experiments is a powerful tool to define the requirements for the 
development of natural products as potential therapeutic agents. The studies described herein 
form an excellent paradigm for the study and development of other natural products.      
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INVESTIGATIONS OF CC-1065, THE DUOCARMYCINS AND SYNTHETIC 
ANALOGUES FOR ANTICANCER PROPERTIES 
(+)-CC-1065 (1) and the duocarmycins (2-9) (Fig. 1) are natural products isolated 
from the culture broth of Streptomyces species, which have been shown to exert ultra-potent 
activity against cultured cancer cells and in experimental animals [1-3]. More recently, (+)-
yatakemycin (10) has been isolated from Streptomyces sp. and represents the most potent 
member of this class of natural products [4]. The biological activity of these natural products 
is related to a characteristic sequence-selective alkylation of adenine N3 in AT-rich sites by 
the least substituted carbon of the activated cyclopropane (Fig. 2) [5, 6]. This minor groove 
binding is thought to initiate a cascade of cellular events leading to apoptosis as observed for 
the duocarmycins [7]. The broad spectrum of antitumour activity and high potency of (+)-CC-
1065 supported its potential as a clinical candidate, unfortunately a delayed death profile due 
to catastrophic hepatotoxicity was observed in experimental animals [8]. It has been 
speculated that this delayed toxicity is related to the degree of reversibility of the DNA 
alkylation and consequently to the extent of non-covalent binding stabilization of the 
reversible DNA adduct [9]. (+)-Duocarmycin SA (DSA, DUMSA, 3) has also been found to 
be too toxic for systemic use, although it is devoid of hepatotoxicity [10]. The failure of the 
clinical progression of CC-1065 and the duocarmycins has prompted many research groups to 
use these natural products as leads for the design of novel, and more efficacious agents with 
reduced adverse toxicity. Since their first isolation, a number of total syntheses of these 
natural products have been extensively reported and reviewed [1, 2]. Additionally, numerous 
investigations have been directed towards the synthesis of authentic alkylating 
pharmacophores and analogues containing deep-seated structural modifications, defining the 
relationship between structure, functional reactivity and biological properties. Exciting 
insights into both the synthetic and mechanistic aspects of this family of natural products have 
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previously been described [1, 2] and the field has recently been further reviewed [11-14]. This 
review serves to update the field over the past decade and will describe novel directions in 
regard to chemical and biological investigations of synthetic analogues and prodrug 
derivatives, which aim to increase tumour selectivity and prepare agents for clinical 
progression. (+)-Yatakemycin (10) and related sandwiched small molecules will not be 
described here, as a recent account of their discovery has already been reported [15]. 
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Figure (1). Structures of (+)-CC-1065, (+)-duocarmycins and (+)-yatakemycin 
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Due to the intense potency, unique mechanism of action and broad range of activity of 
the duocarmycins, extensive efforts have been made during the past two decades to find 
analogues that retain their potency and antitumour activity with potential for clinical 
progression. Early studies of the acid-catalyzed activation of the DNA alkylation reaction 
revealed a direct relationship between stability towards solvolysis and biological potency, and 
this relationship has proved to be general with both simple and full analogues of the natural 
products (for an excellent summary of these studies see ref. [2]). Agents containing the 
natural (CPI, DSA) or modified (CI, CBI, CBQ, CFI) alkylation subunits (Fig. 3) attached to 
the same DNA binding subunits have been found to alkylate DNA at the same sites; the 
distinctions between the agents lie in the greater selectivity among the available sites with 
chemically more stable agents (DSA > CBI > CPI > CBQ > CI).  
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Figure (2). Mechanism of DNA alkylation by the duocarmycins 
 
From thorough examination of the structure-activity relationships (SARs), a parabolic 
correlation between stability and biological activity has been established [16-18]. Compounds 
should possess sufficient stability to enter the cell, yet maintain sufficient reactivity to 
effectively alkylate the DNA upon reaching it [17]. The SARs served to locate the optimal 
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balance point of stability and reactivity that may be used for future design of related 
analogues. The alkylation subunits of DSA (3) and yatakemycin (10) lie at the peak of 
stability/reactivity whereas the CC-1065 (1) and duocarmycin A (2) alkylation subunits fall 
significantly to the over-reactive side of this optimal position [17, 18]. In the following 
sections, highlights from research on various pharmacophores with alkylating potential are 
presented, leading to a discussion on prodrug approaches that are more likely to lead to 
successful candidates for clinical progression.  
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Figure (3). Structures of different alkylating subunits 
 
SAR EXPLORATION ON DNA ALKYLATING PHARMACOPHORES 
 
1,2,7,7a-tetrahydrocyclopropa[c]indol-4-one (CI) 
The first report of the CI subunit was disclosed in the early 1980s [19]. This 
drastically truncated small molecule proved to be an exceptionally reactive electrophile, with 
a DNA alkylation pattern similar to duocarmycin-based agents, albeit with lower efficiency. 
Detailed studies of the CI analogues including introduction of substituents to the phenyl ring  
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(Fig. 4), modification of the minor groove targeting moiety R, and variation of the leaving 
group X of the seco-CI precursor have been reviewed previously [1].  
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Figure (4). Spirocyclisation and alkylation mechanisms of CI-type subunits. 
 
Modifications to the C-6 phenol of seco-CI (Fig. 4, seco-CI numbering) have not been 
extensively investigated. Studies with ethers revealed that the free phenol is not obligatory for 
DNA alkylation; both the alkylating ability and cytotoxicity relates to the electron-donating 
ability of the C-6 substituent (seco-CI numbering), while complete removal of the substituent 
led to a complete loss of activity [20]. This observation led to the exploration of several sub-
classes of amino-seco alkylating pharmacophores based on the CI moiety as potential 
reduction metabolites derived from prodrugs designed to be activated under the hypoxic 
conditions of solid tumours [21]. Assessment of these compounds as cytotoxins is reported 
here in order to compare their reactivity with the parent natural products, but will be put 
further into context under the description of prodrug approaches. Initially, amino and thio 
seco-CI alkylating pharmacophores were investigated and whereas the latter were surprisingly 
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inactive (IC50 > 50-200 M) under the conditions investigated, the amino-seco CIs (11) were 
shown to produce a moderate cytotoxic response, albeit notably less potent than seco-CI itself 
[22]. Subsequent to the preliminary investigation, a wider series of amino-seco compounds 
were synthesized and shown to display similar in vitro potencies (Fig. 5) [23]. In spite of this 
loss of potency, covalent binding to DNA was still observed at the adenine N3 position [21, 
23, 24]. It is tempting to assume the amino-seco CIs spirocyclise in a similar fashion to 
hydroxyl-seco-CI (Fig. 4), and indeed comparison of hypersensitivity factors suggests a 
similar mechanism of action [22]. 
 
6
N
R
O
N
H
OMe
OMe
OMe
11a R = NH2;      IC50 =  0.27 M
11b R = NHMe;   IC50 = 0.11 M
11c R = NMe2;    IC50 = 0.11 M
seco-CI R = OH; IC50 = 0.0022 M
N
NH2
O
N
H
OMe
O
N
NH2
NMe2
11d    IC50 = 0.09 M
O
MeN
NH
11e    IC50 = 0.91 M
Cl Cl Cl
O
nPr
Figure (5) Cytotoxicity of racemic seco-amino-CI analogues against EMT6 murine mammary 
carcinoma cells 
 
A novel class of achiral seco-CI analogues containing the 4-hydroxyphenethyl halide 
functionality instead of the indoline ring (as exemplified by 12) that are able to generate a 
spiro[2,5]cyclopropanecyclohexadienone 13 with capacity to alkylate DNA have been 
reported [25, 26]. These agents react with adenine-N3 with an alkylation pattern similar to 
CC-1065 (Fig. 6) and showed low micromolar cytotoxicity in the NCI panel of 60 human 
tumour cell lines, with a unique pattern of activity that may merit further investigation. In 
particular, compound 12 was very active against melanoma cell lines. A subsequent in vivo 
study with the UACC-257 human melanoma cell line showed activity, with increased mean 
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time for tumour weight doubling of 27.7 days (control 15.8 days) and no bone marrow 
toxicity [25].  
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Figure (6). Achiral CI-TMI analogue 
 
1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) 
CBI-based analogues are synthetically more accessible than the natural products, are 
chemically more stable and retain potent biological activity [2, 27-41]. The CBI subunit has 
found significant applications in prodrug therapy and work in this area is discussed later in 
this review. Recent investigations have included functionalization of the C3 [31], C5 [42] and 
C7 positions [43], and of  the  DNA minor groove binding subunit [27, 29] (Fig. 7). The 
solvolytic reactivity of the C3-substituted halogen series (14a-e) followed the trend of 
increasing reactivity with diminished vinylogous amide stabilization (I > Br > Cl > F > H) 
and their cytotoxic activity (against L1210 cell line) is remarkably less than that of the 
unsubstituted parent N-Boc-CBI itself [31].  The introduction of an ester group at C5 (14g) 
decreased the rate of DNA alkylation while maintaining the DNA alkylation selectivity. The 
C5 ester does not bind in the minor groove of DNA [42]. In contrast, analogues bearing C7 
substituents  (14i –OMe [43] and (14j -CN [44]) had an increased rate of DNA alkylation, 
which was attributed to the fact that the C7-cyano substituent increases the rigid length of the 
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alkylation subunit, leading to an extended degree of DNA binding-induced twist, thus aiding 
the activation of the cyclopropane ring towards nucleophilic attack.  
The CBI-analogues bearing different DNA binding indoles (15, Fig. 7) were assessed 
for their cytotoxicity against L1210 cells and it was found that C5’ substituents (15a-f) had a 
pronounced effect on the biological activity; the cytotoxicity was largely insensitive to the 
electronic character of the C5’ substituent, but sensitive to its size, shape and rigidity [29]. 
Substituents at C7’ (15g-i) had little effect on cytotoxicity.  
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Figure (7). CBI analogues (IC50 data obtained from screening against L1210). All substituents 
(X, Y, Z, R’, R’’) are H unless otherwise indicated. 
 
More complex variations on the minor groove binding right hand subunit have been 
investigated. Analogues containing dimers of monocyclic, bicyclic and tricyclic 
heteroaromatics such as 16 showed a general trend of increasing DNA binding rate and 
efficiency in the order tricyclic (16c) > bicyclic (16b) > monocyclic (16a) heteroaromatic 
subunits with parallel changes in cytotoxicity but no effect on sequence specificity [28]. 
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These results highlight the importance of the minor groove binding domain in catalyzing the 
DNA alkylation reaction, and contain important information for the design of further 
analogues.  
A series of N-aryl (17) and N-alkenyl CBI (18) derivatives [17, 18] showed 
remarkable stability while displaying a well-defined SAR. Electron-withdrawing substituents 
R enhance solvolysis rate and biological activity (eg. 17e, 18b), and electron-donating 
substituents have the opposite effect (eg 17b, 18d). Replacement of the amide linker with an 
alkene as in 18 reduces the cytotoxic potency by approximately 1000-fold [17]. Although the 
unnatural enantiomers are less biologically active than the natural, both natural and unnatural 
enantiomers fit the same SAR relationship. These data played an important role in the 
establishment of the parabolic stability/toxicity relationship described by Boger’s group. 
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Figure (8). CBI analogues bearing aryl and alkenyl DNA-binding subunits. IC50 data obtained 
from L1210 cell line.  
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The synthesis and biological evaluation of racemic and enantiomerically pure amino-
seco-CBI compounds (19, Fig. 9) have been described. In contrast to the CI class (e.g. 11), the 
amino-seco-CBI-TMI compounds showed equipotent activity with the corresponding seco-
phenol compounds (Fig. 9). Structure-activity relationships for several other analogues have 
also been described with the 4’-OMe-cinnamoyl derivative (20) proving to be the most active 
with comparable potency to that of parent CBI-TMI [30, 41, 45, 46].  
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             R = OH; IC50 = 0.21 nM
 
 Figure (9). Amino-CBI analogues. Cytotoxicity assessed in the AA8 CHO cell line 
 
Explorations of CBI analogues with an extended minor groove binding moiety in an 
effort to mimic (+)-CC-1065 have been reported. Compounds (21a-g) (Fig. 10) were tested in 
vitro against U937 and L1210 leukemia cells and in vivo in L1210 tumours in mice with 21a 
being chosen for further investigation. It showed good activity across the NCI 60 tumour cell 
line panel and, in an in vivo experiment, increased the lifespan of mice bearing L1210 
tumours by 107% with low myelosuppression as a side effect. It was also effective against 
B16 melanoma tumours. Unfortunately, further investigations revealed a delayed toxicity 
profile similar to CC-1065, which was attributed to the presence of a methyl group in the C5-
COCH3 substituent since 21e-g did not cause delayed death [40, 47].                                                                                                                                                                                                                                                                                               
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Figure (10). CBI based CC-1065 analogues. Activity against L1210 cells unless otherwise 
indicated 
 
Investigations on the achiral seco-CBI class of agent led to the development of 
compounds (22a-g, Fig. 11) that were more active than the corresponding analogues (12) in 
the CI series described above (Fig. 6) [48]. Compounds with a good leaving group X (e.g. 22a, 
d-g) were found to be over 100-fold more cytotoxic against leukemia L1210 cells than 
analogues bearing a poor leaving group (22c). The achiral 4-amino-1-(2-chloro-ethyl)-
naphthalen-2-yl-TMI (22a) alkylated DNA in a sequence selective manner and had 
substantial in vivo antitumour activity against 12 cell lines in the NCI hollow fibre assay, and 
against MDA-MB-435, SF-295, OVCAR-3 and NCI-H522 subcutaneous tumours when 
administered p.o. or i.v. [48]. 
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Figure (11). Achiral amino-CBI analogues. Cytotoxicity tested against L1210. 
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1,2,8,8a-tetrahydrocyclopropa[c]pyrrolo[3,2-e]indol-4-one (CPI) 
The CPI subunit, which lacks the C7 methyl substituent of CC-1065 and the C6 
methoxycarbonyl group of DSA (Fig. 12), has been investigated with regard to its alkylation 
properties using w794 duplex DNA and cytotoxicity against L1210 cells (Fig. 13). The DNA 
alkylation selectivity of the CPI pharmacophore was shown to be identical to that of the 
natural products. A comparison of the relative rate of DNA alkylation of CPI vs. CC-1065 
and DSA showed that the presence of the C-6 ester in DSA increased the rate and efficiency 
of alkylation, whereas the presence of the C-7 methyl group of CC-1065 caused a slight 
decrease in alkylation rate and efficiency (Fig. 12). This reflects the effect of each group on 
non-covalent binding in the DNA minor groove; the ester enhances binding by increasing the 
overall length of the conjugated system, whereas the steric hindrance of the methyl group 
decreases binding [49]. Structure activity studies (Fig. 13) showed that the methoxy 
substituents of the DSA-TMI group and the extended right-hand chain of CC-1065 are not 
required for sub-nanomolar activity. 
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Figure (12). Comparison of the biological activity of DSA, CPI and Me-CPI compounds. 
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Figure (13). CPI analogues. Activity against L1210 cell line  
 
Extensive SAR studies on modification of the CPI subunit have been reported [50-54] 
including the alteration of the C7 position of the CPI unit bearing either trimethoxy 
indolecarboxyl (TMI) (24a-g) [50] methoxycinnamoyl (25a-g) [50, 53] or acryloylindole (26) 
minor groove binding subunits, (Fig. 14). Among the C7-substituted CPI-TMI analogues the 
C7-methyl (24b), C7-hydroxymethyl (24c), and C7-halogeno (24d) derivatives showed potent 
anti-proliferative activity whereas compounds with electron-withdrawing amide (24f) and 
ester (24a, 24g) groups showed decreased activity. The chloro- (25d) and bromo- (25e) 
methoxycinnamoyl compounds possessed remarkably potent antitumour activity (tumour 
volumes 0.21 and 0.11 of control respectively) with low peripheral blood and bone marrow 
toxicity (and without causing delayed death). The acryloylindole analogues (26) were also 
highly cytotoxic, and showed potent antitumour activity against murine sarcoma 180 (tumour 
volume 0.20-0.25 of control) with lower peripheral blood toxicity compared to DSA [52]. 
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Figure (14). Substitution effect on CPI analogues. Activity against HeLa cells, 1 h exposure 
time  
 
A series of amino-seco DSA analogues (27a-c, Fig. 15) yielded agents possessing 
similar DNA alkylation patterns to the amino-CBI congeners (Fig. 9), albeit 15-60 fold less 
cytotoxic against AA8, EMT6 and SKOV3 cell lines (data from the latter reported in Fig. 15). 
Methylation of the amine (27b, c) provided analogues that were slightly more cytotoxic 
against human cancer cell lines [46]. 
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Figure (15). Amino-seco-DSA analogues (IC50 values from SKOV3 cell line) 
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1,2,9,9a-tetrahydrocyclopropa[c]pyrido[3,2-e]indol-4-one (CPyI) 
Comparative trace metal analyses of cancerous and noncancerous human tissues have 
revealed significant differences that are potentially exploitable from a drug design point of 
view [55]. One study disclosed the synthesis of the 8-ketoquinoline CPyI structure (Fig. 16) 
as a pharmacophore that was expected to provide a tunable means for activation towards 
alkylation via selective metal cation complexation. The activation of CPyI towards 
nucleophilic addition by metal cations was found to directly correspond to the established 
stabilities of the resulting metal complexes (Cu
2+ 
> Ni
2+ 
> Zn
2+ 
> Mn
2+ 
> Mg
2+
), providing the 
opportunity to selectively activate the agents upon addition of the appropriate Lewis acid. The 
CPyI-based agents (28a-28e, Fig. 17) had intrinsic stability comparable to that of CC-1065 
and were more reactive than the corresponding DSA and the CBI-based agents [56, 57]. 
Cytotoxicity is correlated with relative stability, and additionally with the length of the 
molecule, reflecting its capacity for non-covalent interactions with the DNA minor groove. 
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Figure (16). Mechanism of metal cation activation towards DNA alkylation 
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Figure (17).  In vitro cytotoxicity activity of metal-chelating CPyI analogues against L1210  
 
The synthetic route to CPyI molecules lends itself to the preparation of reversed 
analogues such as 29 (Fig. 18) [57]. These maintain the DNA alkylation selectivity inherent to 
all duocarmycin-type molecules, but display a greatly reduced rate of DNA alkylation in the 
absence of an added metal catalyst. On the addition of a cation such as Zn
2+
, the rate and 
efficiency of DNA alkylation increase to equal that of the natural products. In vivo studies and 
potential applications of reversed CPyIs in the treatment of tumours with known differential 
Zn
2+ 
levels have not yet been reported. 
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Figure (18). Reversed CPyI analogue. 
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1,2,8,8a-tetrahydrocyclopropa[c]pyrazolo[4,3-e]indol-4-one (CPzI) 
The N-Boc-CPzI (Fig. 19) alkylating subunit provided a further validation of the linear 
relationship between solvolysis stability, cytotoxic potency and the electron-withdrawing 
properties. The N-Boc derivatives (30) showed modest in vitro activity [58]. Two racemic 
analogues, (31a) and (31b) (closely related to adozelesin (66)) were subsequently synthesized 
and showed picomolar activity in vitro; 31b was shown to possess moderate in vivo activity 
against L1210 tumours in mice [58-60]. The additional electron-withdrawing nitrogen in the 
pyrazole nucleus is proposed to play a similar role to that of the carbomethoxy group of the 
DSA subunit  
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Figure (19). Evaluation of the CPzI compounds. 
 
Other heterocyclic DNA mono-alkylating subunits 
 Interestingly, the examination of the solvolysis and reactivity of a carbocyclic 
analogue, i.e. 1,2,9,9a-tetrahydro-1H-cyclopropa[c]benz[e]inden-4-one,  CBIn (32) (Fig. 20), 
revealed that removal of the nitrogen and resulting vinylogous amide stabilization increased 
the reactivity and reversed the inherent regioselectivity of the alkylation reaction, with attack 
of the nucleophile occurring at the more substituted position of the cyclopropane [33]. 
Thiophene based alkylating subunits MeCTI, (33-35) (Fig. 20) have also been 
reported [16]. It was expected that substitution of the heterocyclic nitrogen with sulfur would 
result in a more stable alkylating subunit than the CPI pharmacophore. Indeed, it was shown 
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that the acid catalyzed solvolysis of N-Boc-MeCTI (33) and N-Boc-iso-MeCTI (34) were 
similar in reactivity but 5-6 fold more stable (t1/2 at pH 3 = 206 and 209 h) than N-Boc-CBI 
(t1/2 = 133 h) and N-Boc-MeCPI (t1/2 = 37 h). Their TMI-derivatives (e.g. MeCTI-TMI, 35) 
were found to be equipotent with (+)-DSA (IC50 = 0.005 nM and 2 nM for the natural and 
unnatural enantiomers respectively in L1210). 
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Figure (20). CBIn and thiophene-based pharmacophores. 
 
X-ray analysis of N-Boc-CBA (36) (Fig. 21) showed the molecule to be almost 
structurally identical with CBI in stereoelectronic alignment of the key cyclopropane, its bond 
lengths, and the bond length of the diagnostic C3a-N2 bond (which reflects the extent of 
vinylogous amide conjugation). Despite these structural similarities, the 1,2,9,9a-
tetrahydrocyclopropa-[c]benz[e]-3-azaindol-4-one (CBA) analogues (37) were found to be 
more prone to solvolysis and hydrolysis, approximately 1000-fold less effective in DNA 
alkylation, and 100-1000-fold lower in cytotoxic activity  than the corresponding CBI 
derivatives [61, 62].  
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Figure (21). CBA analogues with activity against L1201 cells. 
The synthesis and biological investigations of achiral seco-6,7-dicarbomethoxy-CPI 
compounds (Fig. 22) have been disclosed [63]. The ability of compounds (38) and (39) to 
covalently interact with DNA was studied using a thermally-induced DNA cleavage assay. It 
was found that these agents generally showed similar alkylation sequence selectivity to CC-
1065 (1) and adozelesin (66), which supports the concept that the cyclopropane chiral centre 
confined by the indoline is not required for potent biological activities [63]. Indeed, these 
compounds exhibited low nanomolar cytotoxicity against human cancer cells. Further 
cytotoxicity screening of compound 39 conducted against the NCI panel of 60 human cancer 
cell lines found it was particularly active against cell lines derived from patients with lung, 
colon, CNS, skin and breast cancers. 
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Figure (22). Achiral seco-analogues of duocarmycin SA 
 
Preparation of seco-iso-cyclopropylfurano[2,3-e]indoline (seco-iso-CFI (40)) and 
seco-cyclopropyltetrahydro-furano[2,3-f]quinoline (seco-CFQ) (41) classes of agent have 
been reported [64]. The iso-CFI moiety was designed to take advantage of the conjugation of 
the lone pair of electrons of the furan oxygen atom with the cyclopropylindolone moiety (Fig. 
23), providing a second vinylogous conjugation to the pharmacophore and stabilizing the 
cyclopropylindoline functionality toward nucleophilic attack. The CFQ analogues were 
derived from the side product arising from an unexpected lack of selectivity in the radical 
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reaction used to form the chloromethylindoline ring. DNA alkylation studies showed that both 
seco-iso CFI and seco-CFQ covalently interact with the N3 position of adenine residues in the 
minor groove. The cytotoxicity of all the compounds were tested against the NCI panel of 
cancer cell lines and their inhibitory concentrations were observed to be in the low-to 
moderate nanomolar range, with particular activity against solid tumours, most notably 
melanoma and renal carcinoma.   
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Figure (23). IC50 data from the L1210 cell line 
 
Bifunctional alkylating agents 
Investigation of DSA has revealed that the natural (+)-enantiomer alkylates adenine 
N3 within selected AT-rich regions with a binding orientation that extends in a 3’ to 5’ 
direction from the site of alkylation, whereas the unnatural (-)-enantiomer similarly alkylates 
adenine N3, but with a binding orientation that extends in the opposite 5’ to 3’ direction [65]. 
A subsequent study evaluated bifunctional alkylating agents (Fig. 24) against the L1210 cell 
line and demonstrated that the agents containing the natural enantiomer of the alkylating 
subunit (41, 42) were 10-fold more potent than those with the corresponding unnatural 
enantiomer (43, 44) [66]. The alkylating subunit positioned as in the natural products (‘left-
hand’ subunit) also controls the DNA binding orientation and primary site of DNA alkylation; 
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agents with the natural enantiomer in this position acting like (+)-DSA (binding 3’- to 5’ and 
alkylating 5’-AAAA) and agents with the unnatural enantiomer on the left-hand side acting 
like (-)-DSA (binding 5’- to 3’ and alkylating 5’-AAAA) [66].  
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Figure (24). Evaluation of bifunctional alkylating agents against L1210 cells. 
 
Racemic seco-CBI dimers linked through either C7 or N3 via a flexible methylene 
chain (Fig. 25) were tested against the NCI 60 human tumour cell line panel and the order of 
activity was found to be C7-C7 dimer (45) < C7-N3 dimer < N3-N3 (46) dimer, with GI50 
ranging from 41.6 M to 0.0120 M [67]. Antitumour activities were also related to linker 
length and this effect was most noticeable in the C7-N3 series where n = 6 had potencies 
equal to those of the most active N3-N3 compounds; significant selectivities for selected 
tumour types also varied with linker length.   
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Figure (25). Seco-CBI dimers 
 
CPI-based bisalkylators with 5,5’-bis(2-carbonyl)-1H-indole) (47) [69] and 3,3'-(1,4-
phenylene)diacryloyl (48) [68] as rigid linker groups (Fig. 26) have demonstrated that an 
indole-based bisalkylators (47da) was more efficient than bizelesin (68) in vivo (TGI50 = 84 
g/kg against colon 26 murine adenocarcinoma). In general the length of the rigid linker had 
more significant influence on the cytotoxicity and antitumour activity than the type of linker, 
in contrast to previous work that suggested rigid linkers were superior to flexible ones. The 
trifluoromethyl-CPI analogue 48a possessed ultra-potent cytotoxicity (IC50 = 0.0027 nM) and 
showed substantial antitumour activity in vivo (TGI50 = 0.254 mg/kg) with a therapeutic ratio 
(MTD/TGI50 30.7) superior to bizelesin (68) (MTD/TGI50 3.7) [69]. Bisalkylators (49) 
containing 3,3'-arylenebisacryloyl linkers (Fig 27) comprising 1 or 2 aromatic rings exhibited 
potent cytotoxicity and antitumour activity against HeLaS3 human uterine cervix carcinoma 
cells and colon 26 adenocarcinoma cells respectively with 49a being the most active in vitro 
and in vivo (89% TGI at 1.95 mg/kg against murine Co-26 and 83% TGI at 7.81 mg/kg 
against human CX-1 colon tumour models) [70]. 
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Figure (26). CPI bisalkylators containing 3,3'-(1,4-phenylene)diacryloyl linkers. IC50 data 
obtained from HeLaS3 human uterine cervix carcinoma cells. 
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Figure (27). CPI bisalkylators containing 3,3'-(arylene)diacryloyl linkers. IC50 data obtained 
from HeLaS3 human uterine cervix carcinoma cells. 
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Hybrid agents 
Hybrids are generally constructs of different molecular entities of both natural and 
synthetic origin and are synthesized with the hypothesis that combination of structural 
features of two or more biologically active substances into one molecule may enhance or 
modulate the therapeutic characteristics of individual components or lead to a completely new 
properties [71]. In recent years, studies on the combination of duocarmycin-inspired 
alkylating units with alternative minor-groove binders have yielded hybrid molecules with 
novel controllable DNA alkylation and cross-linking abilities. 
A series of hybrids that combined distamycin A-type polypyrrole minor groove 
binders with CPzI alkylating units (50) (Fig. 28) have been described. These water-soluble 
hybrid molecules showed pronounced cytotoxicity against a panel of five tumour cell lines 
and the hybrid compounds generally showed much greater cytotoxicity than that of the CPzI 
unit alone (IC50 = 520 nM for R
2
 = CH3CPzI). In an investigation of the DNA alkylating 
properties, the R
1
 benzyl analogues were found not to cause DNA alkylation and subsequent 
strand cleavage. For the molecule to assume a conformation able to alkylate DNA the benzyl 
group must protrude from the minor groove which is energetically unfavorable. The R
2
 
methyl series efficiently alkylated DNA in AT-rich regions, with the exact sequence 
selectivity depending on hybrid length [72].  
 
N
O
OH
N
N
R2
Cl
N
N
O
NH
N
O
H
N
NH
NH2
n
R1
50a R1 = H, R2 = CH3, n = 1; IC50 = 58 nM
50b R1 = H, R2 = CH3, n = 2; IC50 = 19 nM
50c R1 = H, R2 = CH3, n = 3; IC50 = 7.4 nM
50d R1 = Bn, R2 = H, n = 1;   IC50 = 240 nM
50e R1 = Bn, R2 = H, n = 2;    IC50 = 600 nM
50f  R1 = Bn, R2 = H, n = 3;   IC50 = 400 nM
. HCl
 
Figure (28). CpzI-poylpyrrole hybrids. Activity against L1210 cell line 
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Figure (29). Bleomycin-CBI hybrids 
 
Conjugation of the CBI unit with the DNA-binding domain of bleomycin A2 (a 
glycopeptide antitumour antibiotic with the ability to cleave DNA) caused a marked reduction 
in cytotoxicity of the hybrids (51) (Fig. 29) and no change in DNA sequence selectivity; the 
DNA binding results suggested that the bleomycin domain was acting as an intercalator rather 
than assisting in delivering the CBI alkylating unit to the minor groove [73].  
CPI-lexitropsin hybrids (52) (Fig. 30) containing a trans-alkene linker and n-propyl 
end group bind DNA in AT rich regions with slightly different sequence selectivity to CC-
1065 and with additional alkylation of guanine [74]. Similar compounds such as 53 have been 
prepared [75-77]. Hybrid 53 was shown to alkylate double stranded DNA predominantly at 
the purines of sequence 5’-PyG(A/T)CPu-3’ of both strands (sites 1-3) by co-operative 
homodimer formation, indicating a potential application for duocarmycin hybrids in the 
development of  novel sequence specific DNA-crosslinking agents [75]. Comparison with 
similar agents where the polyamide is directly bonded to the CPI unit showed that the vinyl 
linker in 53 increased DNA alkylation efficiency and biological activity (average IC50 = 5.62 
nM in the Cancer Chemotherapy Centre of Japan’s 39 human cancer cell line panel) [77]. 
Molecular modelling by Lown predicted that a lexitropsin-CBI sandwich hybrid 54 would 
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have enhanced DNA binding affinity and hopefully enhanced biological potency compared to 
the CPI hybrid. The results of biological testing on this compound have not been reported [78].  
This type of compound is amenable to solid phase synthesis using a linker attached to the CBI 
amine, thus facilitating library synthesis [79].  
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Figure (30) Lexitropsin hybrids 
 
Combination of the concepts of hybrid molecules and bifunctional alkylating agents to 
produce seco-CBI-pyrrolo polyamide conjugates 55 and 56 (Fig. 31) containing two racemic 
CBI moieties linked to pyrrole polyamides have been reported [37, 80]. Preliminary 
biological evaluation showed the compounds were active against a panel of 3 human cancer 
cell lines, but notably less so than the corresponding monomers or alkyl-linked dimers, 
leading to the hypothesis that overly large molecules may have poor DNA binding affinity, 
although it has subsequently been shown that very large conjugates can maintain nM activity 
[81].  
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Figure (31). Bifunctional lexitropsin hybrids. Activity: inhibition of growth against the NIH-
H460 NSCLC cell line at 1 mM. 
 
The synthesis of CPI and CBI analogues (Fig. 32) incorporating large 
imidazole/pyrrole polyamide chains for binding double stranded DNA which can target G-C 
base pairs has been reported [81-85]. The incorporation of a vinyl linker between the 
alkylating and minor groove binding agents was again shown to be important for efficient 
DNA alkylation [75]. DNA alkylation by 57a has been shown to inhibit gene transcription by 
alkylation of a site in the gene coding region, suggesting important future applications of 
these molecules [86]. The natural 12S enantiomer of CBI was shown to be an order of 
magnitude more cytotoxic than the unnatural enantiomer in conjugate 57b [84]. Both 
enantiomers of the more complex conjugate 58 showed that the R isomer was a faster and 
more efficient alkylating agents, and that the location of the adenine (site and strand) 
alkylated could be dependent on the isomer used [87]. 
30 
 
N
O
O
N
H
O
N
H
O
O
NH-A-A-A-B
A =
N
Me O
NH
N
N
Me O
NH
B =
N
Me
N
B-A-A-A NH
NH
NMe2
O
O
O
H
N
N
H
N
Me
N H
N
O
Me
N
N
H
O
Mr
N
N
Me O
H
N
N
Me
O
R
N
H
O
N
Me
N
N
H
Ac
57a n = 0, m = 1, R =
n
m
N
H
N
O
CO2Me
57b n = 1, m = 2, R =
N
O
58
 
Figure (32) CPI and CBI compounds containing imidazole and pyrrole polyamide chains. 
 
Investigation of the DNA alkylation properties of enantiomerically pure lexitropsin-
seco-CI hybrids (59) (Fig. 33) revealed that the unnatural R-enantiomers were more potent 
DNA-cleaving agents than the natural S-enantiomers [88]. Molecular modelling suggested 
this was due to the closer proximity of the less substituted carbon of the cyclopropane ring 
(formed in situ) to adenine-N3. The achiral CI moiety has been combined with benzofuran 
and pyrrole/imidazole diamides to produce hybrids such as 60 [89, 90]. These compounds can 
be targeted to alkylate adenine N3
 
flanked by a specific DNA sequence by choice of 
imidazole or pyrrole. These hybrids have reduced cytotoxicity (60 IC50 = 45 M against 
L1210 cells) compared to the parent compound.  
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Figure (33). Lexitropsin-seco-CI hybrids. 
 
A hybrid 61 of the duocarmycin A subunit (produced by hydrolysis of duocarmycin 
B2) with an imidazole-pyrrole polyamide has been reported (Fig. 34) [91]. It was shown that 
the addition of distamycin causes duocarmycins to switch their site of DNA alkylation to N3 
of guanine [92], and further that a synthetic pyrrole/imidazole polyamide can be substituted 
for distamycin to direct the site of DNA alkylation [93]. Hybrids 61 were unreactive with 
DNA in the absence of distamycin; in its presence they readily alkylated guanine of a 
nucleotide sequence designed to match the specific hybrid. This technology can potentially be 
applied to design DNA crosslinking agents with tailored site-selectivity which may have 
potential applications to gene regulation [94, 95]. For example, combination imidazole-
pyrrole-duocarmycin bis-alkylating agents such as 62 have been prepared, which recognizes 
the nine base-pair sequence 5’-PyGGC(T/A)GCCPu-3’, and produce DNA crosslinks only on 
addition of an activating imidazole-imidazole-pyrrole polyamide. 
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Figure (34). Duocarmycin A polyamide conjugate. 
 
Pyrrolobenzodiazepine (PBD) DNA binders have also been examined as hybrids with 
CI and CBI alkylating subunits (Fig. 35). PBD analogues bind specifically to 5’-PuGPu-3’ 
sequences, and react covalently to form stable adducts between the imine group of PBD and 
guanine
2
-NH2 [96]. Since the duocarmycins alkylate DNA on adenine, combining the two 
agents should create compounds capable of creating interstrand crosslinks between mixed AT 
and GC sequences over extended segments of DNA, thus creating biological probes with new 
specificity to interact with novel targets. The prototype CPI-PBD conjugate UTA-6026 (63) 
forms DNA crosslinks across six base-pairs, shows mixed-sequence specific alkylation 
selectivity, and is highly cytotoxic [97]. More recently, publications on the achiral seco-CI-
PBD (64) demonstrated that such hybrids had enhanced cytotoxicity over CI-TMI (5.6 M) or 
amino-CBI-TMI (0.068 M) alone when measured against P815 murine mastocytoma cells. 
Both 63 and 64 were found to induce apoptosis in P815 cells. Amino-CBI-PBD (65) was 
shown to covalently react with adenine-N3 positions within the minor groove at AT-rich 
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sequence, at low concentrations the molecule is selective for a potential interstrand 
crosslinking site [98]. 
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Figure  (35). Pyrrolobenzodiazepine (PBD) hybrid molecules. 
 
CLINICAL CANDIDATES 
Three analogues of CC-1065 (Fig. 36) with improved therapeutic indices have entered 
clinical trials. The monofunctional alkylating agents adozelesin (66) and carzelesin (67) and 
the bifunctional alkylating agent bizelesin (68) have been evaluated in Phase I studies. 
Although administration of these drugs generally was well tolerated with acceptable toxicities 
[99-105] only adozelesin (66) was further investigated in a Phase II trial. Against patients 
with metastatic breast cancer, adozelesin (66) was shown to have only marginal efficacy with 
myelosuppression being the most frequent adverse event [106].  
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KW-2189 (69), a semi-synthetic derivative of duocarmycin B2 (4) [107], was selected 
for clinical trials due to favorable water solubility (10 mg/mL) and antiproliferative activity in 
experimental animal models [108-110]. In spite of the deactivating carbamate functionality, 
KW-2189 (69) has been shown to form a covalent adduct with adenine at N3, although it is a 
1000-fold more active after cleavage of the carbamoyl moiety by carboxyl esterases in vivo 
[110, 111]. KW-2189 (69) has been investigated as a treatment option in patients with 
advanced malignant melanoma [112] and advanced renal cell carcinoma [113]. In both cases, 
KW-2189 (69) did not show sufficient antitumour activity and a low overall objective 
response rate was observed with no further studies warranted against these advanced diseases. 
However, a more recent Phase II trial showed some evidence of antitumour activity in 
patients with hepatocellular carcinoma and further studies against this disease are warranted 
[114]. 
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Figure (36). Clinical candidates. 
 
PRODRUG DEVELOPMENT 
A difficult problem to overcome in cancer treatment is to develop tumour specific 
chemotherapeutic agents that do not expose normal tissue to the effects of cytotoxic agents 
such as adozelesin and bizelesin. There is a belief that this problem, along with issues of 
inability to deliver a curative dose of the agent, unfavorable pharmacological properties such 
as solubility (a notable problem with duocarmycins), and cross-resistance can be overcome by 
the development of prodrug forms of cytotoxic agents. The concept of a cancer prodrug 
requires a tumour-associated enzyme that is able to activate a pharmacologically inactive 
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compound to the corresponding active parent drug in the vicinity of, or within, the tumour. 
The generation of potent cytotoxins within the malignant tissue would improve treatment 
efficacy by allowing higher doses and more frequent treatments, thus minimizing the risks of 
the occurrence of cross-resistant cancer cells. 
A number of different prodrug approaches have been identified, most notably the use 
of prodrug monotherapy, antibody-directed enzyme prodrug therapy (ADEPT) and gene-
directed enzyme prodrug therapy (GDEPT) [115-117]. The success of such strategies depends 
on the difference in cytotoxicity between the prodrug and the corresponding drug as well as 
the high biological activity of the drug. Ultrapotent cytotoxic molecules such as the seco-
duocarmycins are potential candidates in prodrug strategies and this review will in the 
following sections discuss attempts that have been made to improve on the tumour-selectivity 
of the CC-1065 and duocarmycin classes of agent. 
 
Phenol-based prodrug strategies for cancer monotherapy 
It has been demonstrated that duocarmycin and CPI prodrugs formed by acylation of 
the C4 phenol of appropriate seco precursors show improved pharmacokinetics and efficacy. 
For example, several prodrugs (70) of (+)-CBI-Indole2 including carbamates and esters (Fig. 
37) demonstrated picomolar cytotoxicity against L1210 cells, indicating that each prodrug 
was effectively hydrolyzed to release the free seco-drug [34]. Prodrugs 70a and 70b are 
inactive in HCT116 cells (IC50 >1600 pM), suggesting that hydrolysis of tertiary amines was 
not possible in these systems, however 70c-f showed activity in wild type and drug resistant 
cell lines (notably 70d, IC50 = 50 pM in HCT116 w/t and a line with reduced topoisomerase II, 
100 pM in a MDR HCT116 line). 
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Figure (37). Activity against L1210 cells 
 
Glucuronide derivatives of cancer drugs are known to be less toxic, stable in the blood 
stream, and potentially applicable to the treatment of breast cancer, where the level of -
glucuronidase is higher in human breast cancers than in normal cell [118]. A prodrug of CBI 
(Fig. 38) where the phenol is derivatised as the corresponding glucuronide for application as 
monotherapy in -glucuronidase overexpressing tumours has been reported [119]. Both the 
free acid 71a and ester 71b (a double prodrug since the methyl ester is cleaved by 
carboxypeptidases to give 71a) showed potential as prodrugs with an impressive in vitro 
differential in activity in the presence/absence of -glucuronidase. 
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Figure (38) IC50s measured against A549 cell line (absence/presence of -glucuronidase 
respectively) 
The synthesis and antitumour activity of CBI-bearing ester and carbamate prodrugs 
(Fig. 39) has been disclosed. The carbamate prodrugs incorporated methylpiperazine (72a), 
piperidinopiperidine (72b), pyridylpiperidine (72c) and methylhydrazine (72d) whereas the 
ester prodrugs comprise a hexanoic acid ester (72f) and docosahexenoic acid (DHA, 72e). 
These prodrugs are expected to be cleaved by carboxylate esterases to release the free 
cytotoxic metabolite (73), in a similar fashion to carzelesin (67) and KW-2189 (69). The 
DHA conjugate (72e) was of particular interest since DHA is thought to be taken up avidly by 
tumours from nearby blood supplies, and has been shown to have an inhibiting effect on 
tumourigenesis [120]; Previously, it had been shown that conjugation of 10-
hydroxycamptothecin with DHA greatly improved its efficacy [121]. Ester prodrugs were 
found to be more potent than amines, and smaller amines more potent than larger ones, 
indicating their relative resistance to cleavage by carboxylate esterase. In vivo, compounds 
bearing methylpiperazine carbamate (72a) and DHA ester (72e) moieties were found to 
possess the highest therapeutic efficacy, without any delayed toxicity. Although 72e showed 
higher antitumour efficacy than the corresponding free drug in mice bearing L1210 tumours 
the effect was less marked than in the 10-HCT conjugate, and there was no significant 
difference between compound 72e and free drug 73 in mice bearing Lewis lung carcinoma 
suggesting that conjugation with DHA cannot be indiscriminately applied to improve a drug’s 
antitumour activity [47, 122].  
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Figure  (39). Cytotoxicity of racemic compounds against leukemia L1210 cell line.  
 
A series of phenol-based prodrugs with basic C4-O-carbamate moieties (Fig. 40) were 
developed [54]. It was revealed that while compounds 74a-d had poor solubility, they 
possessed good activity in vitro and in vivo activity. Compounds 74a-d were shown to 
possess a varying degree of stability in aqueous solution (1-30h) and enzymatic conversion in 
mouse and human serum. Some analogues such as 74d showed remarkably potent antitumour 
activity in vivo (against murine sarcoma 180 and human St-4 xenografts) with low peripheral 
blood toxicity. Further variants on these compounds included an amine salt on the minor 
groove binding moiety, which was found to be a better strategy for improving water solubility. 
 
 
40 
 
74
R =
N HCl N
N
H2N
NH2
NH2
CH2 N NMe·HBr
74a IC50 = 7.7 nM 74b IC50 = 3.9 nM
74c IC50 = 52 nM
74d IC50 = 11 nM
HN N
O
Br
CO2Me
X2
X1
X3
OCH3
O
75a X1 = N, X2 = H, X3 = H; IC50 = 900 nM (3.3);   T/C 0.36
75b X1 = N, X2 = N, X3 = H; IC50 = 1300 nM (2.5); T/C 0.26
75c X1 = N, X2 = H, X3 = N; IC50 = 1100 nM (0.5); T/C 0.31
75d X1 = H, X2 = H, X3 = N; IC50 = 1300 nM (9.7); T/C 0.50
HN N
O
Br
CO2Me
OCH3
O
O
R
O
N
HCl·MeN
 
Figure (40). In vitro activity against HeLa S3 cells (active drug in parentheses for 75). T/C 
treated/control tumour volumes in sarcoma 180 xenografts.  
 
Preparation of several other carbamate protected duocarmycin prodrugs bearing 4’-
methoxy--heteroarylacryloyl groups as the DNA binding subunit (75) (Fig. 40) have been 
disclosed. Compound 75b proved to have antitumour activity approaching that of KW2189 in 
vivo. All compounds showed comparably low peripheral blood toxicity and increased water 
solubility (>20 mM) compared to that compound bearing the trimethoxyindolyl or 4-
methoxycinnamate side chains as the DNA binding subunit [123]. 
 
Three water-soluble duocarmycin B1 prodrugs (Fig. 41) were prepared by 
incorporating a neutral sugar moiety (76), a phosphoryl group (77) and a N-methylpiperazine 
(78) at the free hydroxyl group. Although these derivatives did not alkylate DNA in vitro, 
they exhibited potent in vitro cytotoxicity and in vivo activity, suggesting that the prodrugs 
41 
 
were activated by enzymatic mechanisms. The carbamate prodrug (78) was most efficacious 
in vivo and had superior water-solubility. In further studies against human tumour xenografts 
resistant to most chemotherapeutic drugs it exhibited potent antitumour activity comparable to 
that of KW-2189 but without this compound’s peripheral blood toxicity [124]. 
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Figure (41). Water-soluble duocarmycin B1 prodrugs. IC50 data obtained from HeLa S3 cells.  
 
Bioreductive prodrugs 
Hypoxia generated as a result of a poor and inefficient neovasculature is a 
characteristic feature of many solid tumours and is associated with the development of an 
aggressive phenotype and resistance to radiotherapy and chemotherapy. The growth of solid 
tumours in vivo beyond 1-2 mm in diameter is associated with the genesis of new blood 
vessels [125]. Even though there is progressive formation of neovasculature, there are areas 
within the tumour that are located at some distance from the blood supply (approx. 50 - 250 
m distance from blood vessels), where the oxygen and nutrient supply is poorly delivered 
[126]. Hypoxia occurs in well-differentiated, slow-growing, non-metastatic tumours as well 
as in rapidly growing, anaplastic, aggressive malignancies. Resistance to chemotherapy and 
radiotherapy is commonly associated with low levels of oxygen in human solid tumours [127]. 
The difference in normal tissue and hypoxic tissue can be exploited by designing drugs that 
are cytotoxic only to cells with a very low oxygen level.  
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Recently N-acyl O-amino phenol prodrugs of CBI-TMI and CBI-indole2 such as 79 
were reported. These compounds were explored for enzymatic reductive activation by 
cleavage of a weak N-O bond by reducing nucleophiles which are thought to be located in the 
hypoxic fractions of tumour cells (Fig. 42). In spite of the NHBoc masking group, the most 
promising compound was equipotent with that of the free seco-drug (IC50 = 0.03 nM against 
L1210) indicating its successful release under the assay conditions [128], although the 
investigators have not indicated whether this is due to chemical instability or enzymatic 
metabolism. Regardless of mechanism of activation, 79 showed superior in vivo activity to 
79a, with improved efficacy and decreased toxicity (in one study 5/6 mice treated with 79 
survived 52 weeks, whereas all those treated with 79a succumbed to drug-related 
complications before this stage).  
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Figure (42). N-acyl O-amino phenol prodrugs of CBI. 
 
A further class of duocarmycin based DNA alkylating agents 81 incorporate the 
quinone moiety of mitomycin A (80) (Fig. 43), which is thought to impart tumour cell 
selectivity as a result of preferential reduction and activation in hypoxic tumours. It has been 
shown that under nonreductive conditions, this quinone analogue did not alkylate DNA even 
at 10
-2
 M concentration, as the oxidized form cannot undergo spirocyclisation to form the 
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reactive cyclopropane. The reduced form, hydroquinone 82, alkylates DNA in a sequence-
specific manner identical to the alkylation pattern of the natural product but does so with 
lower efficiency (100-fold less efficient than duocarmycin SA). A cell-based assay 
established that these analogues, like the mitomycins, were more active in DT-Diaphorase-
enriched cell line (H460) versus a DT-Diaphorase-deficient cell line (H596). Further studies 
confirmed that they are good substrates for human recombinant DT-Diaphorase, establishing 
the viable potential for these and related agents such as 83 to be tumour-selective DNA-
alkylating agents subject to bioreductive alkylation [129]. 
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Figure  (43). Mitomycin A-based compounds. 
 
GDEPT strategy based prodrugs 
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GDEPT is a two-step treatment for patients with solid tumours. Firstly, a gene 
expressing the foreign enzyme is delivered and expressed in the tumour. Secondly, a prodrug 
is administered and converted to a potent cytotoxin by this enzyme [130]. Investigations on 
this concept have led to the use of oxygen-insensitive flavin mononucleotide nitroreductase 
(NTR) as potential enzyme for GDEPT application [131]. The potential cytotoxic metabolites, 
the seco-amino chloromethylindoline-containing molecules, have already been described in 
this review (Fig. 9). A wide variety of nitro-containing aromatic carbamate prodrugs 
including 4-nitrobenzene, 2- and 5-nitroimidazole, nitrothiophene, nitrofuran and other 
substituted carbamates 84a-g (Fig. 44) have been investigated for their use in the NTR 
mediated GDEPT therapy [132-134]. In Fig. 44, selected prodrugs are presented with their 
cytotoxicity values from the resistant SKOV3 cell line (new compounds were also tested 
against WiDr, V79 and EMT6 cell lines in the absence/presence of NTR). Although good 
differential activity was observed in vitro, no significant antitumour activity was observed for 
84a [134], 84d and 84e [132]. 
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Figure  (44). Nitroaryl-carbamate CBI prodrugs as candidates for GDEPT. Ratio = 
Cytotoxicity in the absence and presence of NTR (SKOV3/SKOV3+NTR)  
 
ADEPT strategy based prodrugs 
ADEPT is an attractive approach to overcome the problem of insufficient 
differentiation of normal and malignant cells. As with GDEPT, ADEPT is a two step 
treatment; after administration of an antibody-enzyme conjugate which binds to an antigen 
preferentially expressed on the surface of tumour cells, a non-toxic prodrug is administered 
that is inactive until converted by the tumour cell surface-located enzyme. Ultrapotent 
compounds such as the seco-duocarmycins are potential candidates for [135-142]. The 
synthesis of the glycoside derivatives of seco-CI-TMI (85) (Fig. 45) and the in vitro 
evaluation of its cytotoxic effect has been reported [135]. In spite of its simple structure, as 
discussed earlier, seco-CI-TMI shows a remarkable high cytotoxicity. Exposure of these 
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glycoside prodrugs to cultured carcinoma A549 cells, in the absence and presence of 
glucohydrolase led to a significant differential activity, hence showing the potential for 
ADEPT [135]. 
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Figure  (45). Carbohydrate CI prodrugs as candidates for ADEPT.   
 
The design and synthesis of seco-CBQ galactoside prodrugs such as 86 (Fig. 46) 
containing a secondary chloride that should diminish direct alkylation (which was postulated 
as a reason for unexpectedly high cytotoxicity in a CBI prodrug with a primary chloride 
leaving group [143]) through steric hindrance has been reported [144]. Indeed, it was shown 
that, in the presence of β-D-galactosidase, 86 was very cytotoxic against human bronchial 
carcinoma (A549) and pancreatic ductal adenocarcinoma (PancTu 1) cell lines (IC50 = 0.2 nM 
and 0.13 nM respectively). In contrast, in the absence of the enzyme, the toxicity was 
decreased by 1600-3140 times in the same cell lines [136]. 
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Figure  (46). seco-CBQ galactoside prodrug. 
 
Further galactosylated prodrugs e.g. 87 were designed to reduce cytotoxicity prior to 
tumour-specific metabolism by incorporating the chloroethyl seco group (Fig. 47). In vitro 
evaluation of two isomers was carried out against human bronchial carcinoma A549 cells in 
absence and in the presence of β-D-galactosidase. Interestingly, the two diasteroisomers 
shows considerable difference in their activity and it was found that the anti-isomer (IC50 = 
1.3 nM) was more than 200-fold active than the syn-isomer (IC50 = 280 nM) in presence of 
the enzyme [136, 143]. 
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Figure  (47). Methyl seco-CBI galactoside prodrug. 
 
Recent publications have described further prodrugs 88 (Fig. 48) where the phenolic 
hydroxyl group is protected as glycoside. The N,N-dimethylaminoethoxyindole carboxylic 
acid component facilitates binding in the DNA minor groove and increases water solubility 
[137, 145]. When tested against the A549 cell line, the galactoside 88a exhibited micro molar 
activity, but significantly was shown to be more than 5000-fold active in the presence of β-D-
galactosidase (IC50 = 0.75 nM). In contrast, the (-)-diasteromeric seco-agent showed activity 
1000-fold lower than that of (+)-isomer [138, 145, 146]. Investigation of the role of the sugar 
moiety found that the identity of this group was important for prodrug stability; after 24 h 
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exposure to culture medium, the prototype galactoside 88a was 72% hydrolyzed, whereas 
88b-e were 94-98% intact [141].  
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Figure (48). IC50 data obtained from A549 cell line in absence/presence of relevant 
glycosidase. 
 
Compound 89, which consists of a conjugate of a seco-analogue of CBI and 
cephalosporin (Fig. 49) was designed to be activated by β-lactamases. However, the success 
of this ADEPT approach was limited due the capacity of 88 to readily form the 
spirocyclopropanehexadienone pharmacophore in non-malignant tissue [147]. In a similar 
vein, glucuronide derivatives were also prepared, for example of CBI analogues (90), which 
showed a slight decrease in toxicity compared to the de-glucuronidated compound (IC50 = 0.6 
nM vs. 0.1 nM against U937 leukemia cells) leading the authors to conclude such agents 
would be more applicable as conventional cytotoxics rather than prodrugs [148].  
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Figure (49). Prodrugs of the seco-CBI pharmacophore. 
 
Further drug-conjugate strategies 
There has been a recent resurgence of interest in the use of covalently-linked 
antibodies to deliver highly cytotoxic drugs to tumours [149]. Due to their picomolar activity, 
derivatives of duocarmycins are well-suited for this application. The CBI-based analogue 91 
(Fig. 50) was conjugated to antibodies anti-B4 (against CD19) and N901 (against CD56). The 
anti-B4 conjugate was highly potent (IC50 ~0.1 nM) and completely cured mice bearing large 
Namalwa B-cell lymphoma tumours [150].  
Duocarmycins have also been delivered to tumour cells by a polyethyleneglycol 
(PEG)-dipeptide linker [151, 152].  The derivative DU-257 92 (Fig. 50) was attached via a 
PEG-dipeptide linker to monoclonal antibody KM231, which specifically recognizes sialyl 
Lewis a (sLe
a
) carbohydrate antigen. The conjugate was stable in aqueous solution, and was 
shown to be specifically activated by SW1116 colorectal adenocarcinoma cells, but a low 
level of drug release and availability of material precluded a full investigation of the 
conjugate’s efficacy [152]. 
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Figure (50). CBI and DU-257 antibody conjugates. 
 
Preparation of seco-CPyI and seco-amino-CBI derivatives conjugated with enzymes 
through a linker on the phenol or amino moiety respectively have been reported (Fig. 51) 
[153]. 93 and 94 were suitable for conjugation with enzymes without causing aggregation 
(which arises from poor drug solubility). Conjugation with an anti-CD30 antibody reduced 
cell growth to < 25% of control. The conjugate of 93 with antibody cBR96 was more 
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cytotoxic than doxorubicin or cisplatin to NCI-H69 cells with high levels of P-glycoprotein 
(IC50 = 13.4 nM) and multi-drug resistant NCI-H69/LX4 cells (IC50 = 20.7 nM). 
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Figure (51). seco-amino-CBI and seco-CpyI conjugates.  
 
The CBI phenol ester prodrug 95 (Fig. 52) was designed to bind to human serum 
albumin in the blood stream [154], which would lead to preferential take-up by tumour tissue 
which has an affinity for human serum albumin (HSA) [155].  The conjugate 95 has reduced 
cytotoxicity compared to the free phenol (3 x more prodrug could be dosed without causing 
weight loss, and prodrug-induced weight loss was well-tolerated, no delayed death occurred) 
and effective in xenograft models. In a colon 38 model, 50% of mice were cured at 0.3 mg/kg 
with tumour growth inhibition of 99%, significantly better than free phenol (76%) and 5-FU 
(TGI  95% but no cures). In a SKOV3 model, TGI was 52% compared to 22% with paclitaxel. 
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Figure (52). CBI-ester prodrug. 
 
CONCLUSION 
Due to the intense potency, unique mechanism of action and broad range of 
antitumour activity of CC-1065 and the duocarmycins, much research has been 
conducted on these families of natural products since their isolation just over 
30 years ago. As highlighted in this review, many research groups around the 
world still continue to explore new directions in this field. The past decade 
has added yet another level to our understanding of these unique compounds 
through many structure-activity relationship studies. Sadly, in spite of these 
extensive investigations, only four agents have entered clinical evaluation to 
date – and with disappointing results. However, it is this unmet clinical 
potential that has driven research groups in this field to perhaps change 
direction to that of development of prodrug approaches, which aims at 
selectively releasing potent analogues of CC-1065 and duocarmycins only in 
malignant tissue. Many investigations have focused on inactivating the 
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alkylating pharmacophore by masking the chloromethylindoline unit of the 
seco-duocarmycins with electron-withdrawing groups including carbamates on the C6 phenol. 
Although good differential activity and improved pharmacokinetics in preclinical models 
have been observed, the clinical trials with carzelesin and KW-2189 have not 
corroborated this prodrug approach. 
The success of prodrug strategies depends on the difference in cytotoxicity 
between the prodrug and the corresponding cytotoxic metabolite. Accordingly,  
there is no doubt that the seco-duocarmycins lend themselves to being great 
candidates for use in prodrug strategies due to their structural architecture 
and inherent cytotoxic potential. This review has highlighted the emerging 
potential of some of these agents in monotherapy, ADEPT and GDEPT strategies. 
Fine-tuning these strategies may in the near future lead to drugs that are 
selectively unmasked in malignant tissue, leading to improved treatment 
efficacy of patients with solid tumours. 
 
ABBREVIATIONS 
ADEPT Antibody-directed enzyme prodrug therapy 
CBA  1,2,9,9a-tetrahydrocyclopropa-[c]benz[e]-3-azaindol-4-one 
CBI  1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one 
CBIn  1,2,9,9a-tetrahydro-1H-cyclopropa[c]benz[e]inden-4-one 
CBA  1,2,9,9a-tetrahydrocyclopropa-[c]benz[e]-3-azaindol-4-one 
CBQ  2,3,10,10a-Tetrahydro-1H-cyclopropa[d]benzo[f]quinol-5-one 
CFI  Cyclopropylfurano[2,3-e]indoline 
CFQ  Cyclopropyltetrahydro-furano[2,3-f]quinoline 
CI  1,2,7,7a-tetrahydrocyclopropa[c]indol-4-one 
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CNS  Central nervous system 
CPI  1,2,8,8a-tetrahydrocyclopropa[c]pyrrolo[3,2-e]indol-4(5H)-one 
CPyI  1,2,9,9a-tetrahydrocyclopropa[c]pyrido[3,2-e]indol-4-one 
CPzI  1,2,8,8a-tetrahydrocyclopropa[c]pyrazolo[3,2-e]indol-4(5H)-one 
CTI  1,2,8,8a-tetrahydrocyclopropa[c]thieno[3,2-e]indol-4-one 
DHA  Cis-4,7,10,13,16,19-docosahexenoic acid 
DNA  Deoxyribonucleic acid 
DSA  (+)-Duocarmycin Stable A 
ED50  Effective Dose for 50% response 
FDI  5-[(5-fluoro-1H-indol-2-ylcarbonyl)amino]-1H-indol-2-yl]carbonyl 
GDEPT Gene-directed enzyme prodrug therapy 
GI50  drug concentration required for 50% Growth Inhibition 
HCT  Hydroxycamptothecin 
HSA  Human serum albumin 
IC50  half maximal Inhibitory Concentration 
MeCTI 7-Methyl-1,2,8,8a-tetrahydrocyclopropa[c]thieno[3,2-e]indol-4-one 
MTD  Maximum tolerated dose 
NCI  National Cancer Institute 
NTR  Nitroreductase 
PBD  Pyrrolobenzodiazepine 
PEG  Polyethyleneglycol 
SAR  Structure-activity relationship 
TGI  Tumour growth inhibition  
TMI  Trimethoxyindole 
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